Featured
-
These researchers are shaping the future of women in STEM
In honor of the 2026 Women’s History Month, the Vanderbilt University School of Medicine Basic Sciences is highlighting female faculty from our school. We asked them to reflect on their journeys and the changes they have experienced in how biomedical research and academia treat their women. Read MoreMar. 25, 2026
-
Meet the departments: Unraveling the mysteries of human cells one discovery at a time
Department of Cell and Developmental Biology faculty are unraveling the mysteries of human cells one discovery at a time. Read MoreMar. 12, 2026
-
Katrin Karbstein named vice chair of biochemistry
Katrin Karbstein, the co-leader of the Cancer Cell Biology Research Program in the Vanderbilt-Ingram Cancer Center, will now expand her focus to support her department’s mission across research, service, and education, with a special focus on faculty affairs. Read MoreFeb. 19, 2026
-
Neuroscientist Shan Meltzer named 2026 Sloan Research Fellow
Shan Meltzer was named a Sloan Research Fellow, one of the most competitive honors available to young investigators, for her research into how the neural circuits responsible for touch and pain processing are built and organized. Read MoreFeb. 17, 2026
-
ASPIRE Down the Road: Exploring the local pharmaceutical industry in Nashville
Vanderbilt trainees and postdocs explored Nashville’s biotech scene, starting with contract research organization Inotiv. Read MoreFeb. 10, 2026
-
School of Medicine Basic Sciences: 2025 in review
As 2025 draws to a close, we reflect on the achievements and contributions to science made by the School of Medicine Basic Sciences community over the past year. SOMBS facilitates outstanding fundamental science research across four departments, two institutes, 10 centers, and 18 core facilities. The work of our faculty,… Read MoreDec. 17, 2025
-
Osheroff lab provides mechanistic data in successful FDA application for new gonorrhea treatment
The U.S. Food and Drug Administration has approved the use of the new antibiotic gepotidacin for use against uncomplicated gonorrhea. The biochemistry lab of Neil Osheroff provided all mechanism of action data in the FDA application. Read MoreDec. 11, 2025
-
Second schizophrenia treatment discovered at Vanderbilt’s Warren Center enters phase I clinical trial
A new potential treatment for schizophrenia discovered through the Warren Center for Neuroscience Drug Discovery at Vanderbilt University has entered phase 1 clinical trials, marking the fifth WCNDD therapeutic to advance into human testing. Read MoreNov. 12, 2025
-
From Lab to Legacy: Marnett’s Trainees Gather to Toast a Life in Science and Service
In a heartwarming tribute to a remarkable career, more than 70 of his former graduate students and postdoctoral scholars recently traveled from across the globe for a three-day festivity on Oct. 3–5 to celebrate Larry Marnett’s 50 years in academia. Read MoreOct. 20, 2025
-
Vanderbilt scientist tackles key roadblock for AI in drug discovery
Vanderbilt’s Dr. Benjamin P. Brown is improving the way the field of drug discovery creates machine learning algorithms to predict a protein’s interactions with a small molecule. These improvements bring ML closer to fulfilling its potential in the field—something that has not been realized after more than a decade of work. Read MoreOct. 16, 2025